MARKET

AKTX

AKTX

Akari Therapeutics Plc
NASDAQ
3.006
+0.006
+0.19%
Closed 16:00 10/04 EDT
OPEN
2.987
PREV CLOSE
3.000
HIGH
3.006
LOW
2.760
VOLUME
3.43K
TURNOVER
--
52 WEEK HIGH
4.400
52 WEEK LOW
1.078
MARKET CAP
36.50M
P/E (TTM)
-1.8439
1D
5D
1M
3M
1Y
5Y
1D
Weekly Report: what happened at AKTX last week (0923-0927)?
Weekly Report · 6d ago
Weekly Report: what happened at AKTX last week (0916-0920)?
Weekly Report · 09/23 09:59
Akari Therapeutics Merges with Peak Bio to Advance Autoimmune Treatments
TipRanks · 09/18 20:58
ROB BAZEMORE APPOINTED TO THE BOARD OF DIRECTORS OF AKARI THERAPEUTICS
Reuters · 09/17 12:05
ROB BAZEMORE APPOINTED TO THE BOARD OF DIRECTORS OF AKARI THERAPEUTICS
Reuters · 09/17 12:00
Weekly Report: what happened at AKTX last week (0909-0913)?
Weekly Report · 09/16 09:54
Weekly Report: what happened at AKTX last week (0902-0906)?
Weekly Report · 09/09 09:59
AKARI THERAPEUTICS FILES PROSPECTUS FOR RESALE BY SELLING SHAREHOLDERS OF UP TO 21.56 BLN ORDINARY SHARES - SEC FILING
Reuters · 09/06 21:26
More
About AKTX
Akari Therapeutics, Plc is a late-stage biotechnology company. The Company is developing advanced therapies for autoimmune and inflammatory diseases. Its lead asset, investigational nomacopan, is a bispecific recombinant inhibitor of complement C5 activation and leukotriene B4 (LTB4) activity. Its pipeline includes a Phase 3 clinical trial program investigating nomacopan for pediatric hematopoietic stem cell transplant-related thrombotic microangiopathy (HSCT-TMA). It is conducting a clinical trial of subcutaneous nomacopan for the treatment of HSCT-TMA in pediatrics. The United States Food and Drug Administration (FDA) has granted Rare Pediatric Disease, Orphan Drug, and Fast Track designations to nomacopan for the treatment of pediatric HSCT-TMA. It is also investigating long-acting PASylated-nomacopan (PAS-nomacopan) for treatment of geographic atrophy (GA) secondary to dry age-related macular degeneration (dry AMD) in preclinical studies.

Webull offers Akari Therapeutics PLC (ADR) stock information, including NASDAQ: AKTX real-time market quotes, financial reports, professional analyst ratings, in-depth charts, corporate actions, AKTX stock news, and many more online research tools to help you make informed decisions. Trade stocks for 0 commission and 0 contract fees on the web version for easy and convenient access, or download the Webull app and trade on the go.

You can practice and explore trading AKTX stock methods without spending real money on the virtual paper trading platform.